Avidity Biosciences Inc
RNAM
NASDAQ Global Market72.86
USD
+0.04
- -
Avidity Biosciences Inc
RNAM
(NASDAQ Global Market)
Recent
price
72.86
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Avidity Biosciences, Inc. engages in the discovery, development, and delivery of RNA therapeutics using its proprietary antibody oligonucleotide conjugate (AOC) platform to address targets and diseases previously inaccessible to conventional RNA therapies. The company develops targeted RNA therapeutics that combine monoclonal antibody–level tissue specificity with oligonucleotide precision, aiming to treat rare muscle diseases and other genetic disorders. Through its pipeline, the firm focuses on Duchenne muscular dystrophy, myotonic dystrophy type 1, and facioscapulumer muscular dystrophy, among others, leveraging AOC technology to enhance tissue targeting and therapeutic delivery. Founded in 2020 and headquartered in San Diego, California, Avidity operates with a multi-disciplinary team to advance clinical programs and explore additional indications via collaboration and internal expansion. Its core products and services include research and development of antibody oligonucleotide conjugates (AOC) across discovery, preclinical development, and clinical-stage programs; platform optimization for targeted RNA delivery; biomarker and translational studies to support trial design; and strategic collaborations to expand the therapeutic reach of its AOC portfolio. Latest major company changes encompass advances in its pipeline progression and strategic partnerships designed to bolster clinical development and manufacturing capabilities, as well as potential portfolio expansions through collaborations or licensing agreements. The company also reports ongoing updates to its clinical trial activities, regulatory submissions, and potential commercial strategy developments as part of its broader corporate evolution in the last 1–2 years. Industry context and segments: biotechnology; biopharmaceuticals; RNA therapeutics; targeted delivery platforms; rare genetic diseases and muscular dystrophies. Target markets include global clinical-stage biopharma partners, contract development and manufacturing organizations, academic collaborators, and patient communities seeking novel RNA-based treatments. Geographic operations span the United States with ongoing research and development activities typically supported by external partnerships and potential international trial sites, alongside headquarters and corporate offices in North America. Subsidiaries and parent relationships are aligned with corporate structure typical of a clinical-stage biopharma company pursuing external collaborations to advance its AOC platform and pipeline compounds.